State-of-the-Art PaperThe Use of Digoxin in Patients With Worsening Chronic Heart Failure: Reconsidering an Old Drug to Reduce Hospital Admissions
Key Words
Abbreviations and Acronyms
Cited by (0)
Dr. Butler receives research support from the National Institutes of Health, the Health Resources and Services Administration, the European Commission, Amgen, Medtronic, Novartis, and Otsuka; and is a consultant for Alere, Bayer, BG Medicine, Celadon, CardioMEMS, Gambro, Medpace, Ono, Reate, Takeda, and Trevena. Dr. Gheorghiade is a consultant for Abbott Laboratories, Astellas, AstraZeneca, Bayer Schering Pharma, Bayer HealthCare, Cardiorentis, CorThera, Cytokinetics, CytoPherx, DebioPharm, Errekappa Terapeutici, GlaxoSmithKline, Ikaria, Johnson and Johnson, Medtronic, Merck, Novartis Pharma, Ono Pharma USA, Otsuka Pharmaceuticals, Palatin Technologies, Pericor Therapeutics, Protein Design Laboratories, Sanofi-Aventis, Sigma Tau, Solvay Pharmaceuticals, Sticares InterACT, Takeda Pharmaceuticals, and Trevena Therapeutics. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose.